BRAF and familial papillary or follicular thyroid carcinoma: Therefore, BRAF V600E and TERT promoter mutations were also used as the evaluation indicators of FNMTC aggressiveness and was compared with SNMTC; the difference between them was not statistically significant (p > 0.05).